Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs BIO-TECHNE Corp — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.6, while BIO-TECHNE Corp trades at $72.22 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Global X Artificial Intelligence & Technology ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $72.29 |
52-Week Low | $43.88 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.69, up 0.28% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock recently crossed above its 200-day moving average of $56.52, indicating positive momentum. Recent news highlights AIQ's outperformance versus the Nasdaq and its role in the AI investment theme, though financial ratios are not provided in the snapshot.
The outlook for AIQ is tied to the AI sector's growth, with potential from thematic exposure and rebalancing strategies. Risks include high fees, sector volatility, and dependence on AI adoption trends. Analyst sentiment is mixed, with some praising diversification benefits while others note valuation concerns amid rapid gains.
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
